BioLineRx (BLRX) Pops Higher on BL-8020 Phase I/II Plans
Tweet
Share
E-mailGet Alerts BLRX Hot Sheet
Join SI Premium – FREE
BioLineRx (Nasdaq: BLRX) shares are ripping in pre-market trading Tuesday following an update on BL-8020. Shares are 11 percent higher ahead of the bell.
According to a release out earlier, "[BioLineRx] has successfully completed the pre-clinical development of BL-8020, an orally available, interferon-free treatment for the Hepatitis C virus (HCV), and plans to commence a Phase I/II safety and efficacy study for BL-8020 in Europe during the first quarter of 2013."
According to a release out earlier, "[BioLineRx] has successfully completed the pre-clinical development of BL-8020, an orally available, interferon-free treatment for the Hepatitis C virus (HCV), and plans to commence a Phase I/II safety and efficacy study for BL-8020 in Europe during the first quarter of 2013."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SK bioscience files RSV antibody trial application in South Africa
- Biomea Fusion doses first patient in obesity combo drug study
- BAE Systems advances to Phase 2 of DARPA's THREADS program
Create E-mail Alert Related Categories
FDA, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
